Rupatadina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rupatadina" in Italian language version.

refsWebsite

Global rank Italian rank

16nih.gov

4^th place

9^th place

9doi.org

2^nd place

7^th place

8oadoi.org

799^th place

22^nd place

doi.org

dx.doi.org

Picado C, Rupatadine: pharmacological profile and its use in the treatment of allergic disorders, in Expert Opin Pharmacother, vol. 7, n. 14, ottobre 2006, pp. 1989–2001, DOI:10.1517/14656566.7.14.1989, PMID 17020424.
Wardlaw AJ, Moqbel R, Cromwell O, Kay AB, Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils, in J. Clin. Invest., vol. 78, n. 6, dicembre 1986, pp. 1701–6, DOI:10.1172/JCI112765, PMC 423945, PMID 3023451.
Katiyar S, Prakash S, Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis, in Prim Care Respir J, vol. 18, n. 2, giugno 2009, pp. 57–68, DOI:10.3132/pcrj.2008.00043, PMID 18695846.
Mullol J, Bousquet J, Bachert C, et al., Rupatadine in allergic rhinitis and chronic urticaria, in Allergy, 63 Suppl 87, aprile 2008, pp. 5–28, DOI:10.1111/j.1398-9995.2008.01640.x, PMID 18339040.
Metz M, Maurer M, Rupatadine for the treatment of allergic rhinitis and urticaria, in Expert Rev Clin Immunol, vol. 7, n. 1, gennaio 2011, pp. 15–20, DOI:10.1586/eci.10.85, PMID 21162645.
Solans A, Izquierdo I, Donado E, et al., Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study, in Clin Ther, vol. 30, n. 9, settembre 2008, pp. 1639–50, DOI:10.1016/j.clinthera.2008.09.002, PMID 18840369.
Solans A, Carbó ML, Peña J, Nadal T, Izquierdo I, Merlos M, Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study, in Clin Ther, vol. 29, n. 5, maggio 2007, pp. 900–8, DOI:10.1016/j.clinthera.2007.05.004, PMID 17697908.
Fité R, Borja J, Rupatadine and heart rhythm disturbances, in Clin. Pharmacol. Ther., vol. 87, n. 1, gennaio 2010, pp. 37; author reply 37–8, DOI:10.1038/clpt.2009.118, PMID 19727070.
Carvajal A, Macías D, Salado I, et al., Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese pharmacovigilance systems, in Clin. Pharmacol. Ther., vol. 85, n. 5, maggio 2009, pp. 481–4, DOI:10.1038/clpt.2008.269, PMID 19225450.

nih.gov

ncbi.nlm.nih.gov

Merlos M, Giral M, Balsa D, et al., Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF), in J. Pharmacol. Exp. Ther., vol. 280, n. 1, gennaio 1997, pp. 114–21, PMID 8996188.
Picado C, Rupatadine: pharmacological profile and its use in the treatment of allergic disorders, in Expert Opin Pharmacother, vol. 7, n. 14, ottobre 2006, pp. 1989–2001, DOI:10.1517/14656566.7.14.1989, PMID 17020424.
Pretolani M, Vargaftig BB, From lung hypersensitivity to bronchial hyperreactivity. What can we learn from studies on animal models?, in Biochem. Pharmacol., vol. 45, n. 4, febbraio 1993, pp. 791–800, PMID 8452553.
Wardlaw AJ, Moqbel R, Cromwell O, Kay AB, Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils, in J. Clin. Invest., vol. 78, n. 6, dicembre 1986, pp. 1701–6, DOI:10.1172/JCI112765, PMC 423945, PMID 3023451.
Pretolani M, Ferrer-Lopez P, Vargaftig BB, From anti-asthma drugs to PAF-acether antagonism and back. Present status, in Biochem. Pharmacol., vol. 38, n. 9, maggio 1989, pp. 1373–84, PMID 2655601.
Katiyar S, Prakash S, Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis, in Prim Care Respir J, vol. 18, n. 2, giugno 2009, pp. 57–68, DOI:10.3132/pcrj.2008.00043, PMID 18695846.
Valero A, Serrano C, Bartrá J, et al., Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study, in J Investig Allergol Clin Immunol, vol. 19, n. 6, 2009, pp. 488–93, PMID 20128424.
Mullol J, Bousquet J, Bachert C, et al., Rupatadine in allergic rhinitis and chronic urticaria, in Allergy, 63 Suppl 87, aprile 2008, pp. 5–28, DOI:10.1111/j.1398-9995.2008.01640.x, PMID 18339040.
Keam SJ, Plosker GL, Rupatadine: a review of its use in the management of allergic disorders, in Drugs, vol. 67, n. 3, 2007, pp. 457–74, PMID 17335300.
Metz M, Maurer M, Rupatadine for the treatment of allergic rhinitis and urticaria, in Expert Rev Clin Immunol, vol. 7, n. 1, gennaio 2011, pp. 15–20, DOI:10.1586/eci.10.85, PMID 21162645.
Valero A, de la Torre F, Castillo JA, et al., Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain, in Drug Saf, vol. 32, n. 1, 2009, pp. 33–42, PMID 19132803.
Solans A, Izquierdo I, Donado E, et al., Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study, in Clin Ther, vol. 30, n. 9, settembre 2008, pp. 1639–50, DOI:10.1016/j.clinthera.2008.09.002, PMID 18840369.
Solans A, Carbó ML, Peña J, Nadal T, Izquierdo I, Merlos M, Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study, in Clin Ther, vol. 29, n. 5, maggio 2007, pp. 900–8, DOI:10.1016/j.clinthera.2007.05.004, PMID 17697908.
Mion Ode G, Campos RA, Antila M, et al., Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis, in Braz J Otorhinolaryngol, vol. 75, n. 5, 2009, pp. 673–9, PMID 19893935.
Fité R, Borja J, Rupatadine and heart rhythm disturbances, in Clin. Pharmacol. Ther., vol. 87, n. 1, gennaio 2010, pp. 37; author reply 37–8, DOI:10.1038/clpt.2009.118, PMID 19727070.
Carvajal A, Macías D, Salado I, et al., Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese pharmacovigilance systems, in Clin. Pharmacol. Ther., vol. 85, n. 5, maggio 2009, pp. 481–4, DOI:10.1038/clpt.2008.269, PMID 19225450.

oadoi.org

Picado C, Rupatadine: pharmacological profile and its use in the treatment of allergic disorders, in Expert Opin Pharmacother, vol. 7, n. 14, ottobre 2006, pp. 1989–2001, DOI:10.1517/14656566.7.14.1989, PMID 17020424.
Katiyar S, Prakash S, Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis, in Prim Care Respir J, vol. 18, n. 2, giugno 2009, pp. 57–68, DOI:10.3132/pcrj.2008.00043, PMID 18695846.
Mullol J, Bousquet J, Bachert C, et al., Rupatadine in allergic rhinitis and chronic urticaria, in Allergy, 63 Suppl 87, aprile 2008, pp. 5–28, DOI:10.1111/j.1398-9995.2008.01640.x, PMID 18339040.
Metz M, Maurer M, Rupatadine for the treatment of allergic rhinitis and urticaria, in Expert Rev Clin Immunol, vol. 7, n. 1, gennaio 2011, pp. 15–20, DOI:10.1586/eci.10.85, PMID 21162645.
Solans A, Izquierdo I, Donado E, et al., Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study, in Clin Ther, vol. 30, n. 9, settembre 2008, pp. 1639–50, DOI:10.1016/j.clinthera.2008.09.002, PMID 18840369.
Solans A, Carbó ML, Peña J, Nadal T, Izquierdo I, Merlos M, Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study, in Clin Ther, vol. 29, n. 5, maggio 2007, pp. 900–8, DOI:10.1016/j.clinthera.2007.05.004, PMID 17697908.
Fité R, Borja J, Rupatadine and heart rhythm disturbances, in Clin. Pharmacol. Ther., vol. 87, n. 1, gennaio 2010, pp. 37; author reply 37–8, DOI:10.1038/clpt.2009.118, PMID 19727070.
Carvajal A, Macías D, Salado I, et al., Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese pharmacovigilance systems, in Clin. Pharmacol. Ther., vol. 85, n. 5, maggio 2009, pp. 481–4, DOI:10.1038/clpt.2008.269, PMID 19225450.